Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by RazeKreationson Apr 04, 2022 2:33pm
152 Views
Post# 34573983

BNN Bloomberg

BNN BloombergBNN Bloomberg states that the Tsx is 33% undervalued. While the Nasdaq 100 is 35% overvalued. Good time to invest in Canadian stocks Why does the TSX look so good? First, the fair market value of the TSX is positive, being 33 per cent higher than its current price. The NASDAQ 100, even after its setback, remains 35 per cent over-valued, while the S&P is about 10.8 per cent over-valued, although if I eliminate the FANGs from the S&P 500 weightings, the FMV potential of the S&P 500 is a modest but positive +0.2 per cent. I believe that there are still good value opportunities in that index. Second, the TSX is a commodity index, and during inflation and shortages, this is where one should be. Third, the pendulum swings between the U.S. and the Canadian stock markets in terms of the best place to be. After 12 years of underperformance, it is swinging back to Canada, as the country is far cheaper and less risky that the general U.S. markets. Going forward, Canada will remain an investment market and the U.S. a trading market. There will be lots of opportunities to play rebounds in the U.S. although you will need to be nimble which is the sort of information that our SVA service provides our clients.
<< Previous
Bullboard Posts
Next >>